Real-time funding, M&A, exec moves & hiring — the signals that move deals
More real-time opportunities that match your ICP — every funding, M&A, and exec move the moment it breaks, with the verified contacts to reach out first.
Funding, M&A, exec moves & hiring — every signal Fundz sees, the moment it happens. See who’s in your market, who to reach, and why now.
Summit Therapeutics Inc.
www.smmttx.comAI Executive Summary
AI-powered analysis of 8-K filing content
Summit Therapeutics announced updated overall survival analysis results from its Phase III HARMONi trial showing promising trends for ivonescimab combined with chemotherapy in treating EGFR-mutated advanced non-small cell lung cancer, with consistent results across western and Asian patient populations.
Key Takeaways
Phase III HARMONi trial data shows consistent overall survival trends for ivonescimab plus chemotherapy versus placebo in previously treated EGFR-mutated non-small cell lung cancer patients
Analysis includes data from both western and Asian patient populations, demonstrating broad applicability of the treatment approach
2 more takeaways
Related Filings (1)
1 more filing from Summit Therapeutics Inc. in the last 90 days